anmelden
OMX Copenhagen 20
1.539,57
PKT
+38,10
PKT
+2,54
%
Handle Aktien, ETFs, Derivate & Kryptos ohne Ordergebühren (zzgl. Spreads) beim ‘Kostensieger’ finanzen.net zero (Stiftung Warentest 12/2025)
Werbung
Analysen zu OMX Copenhagen 20-Werten
| Datum | Rating | Analyst | |
|---|---|---|---|
| 03.11.22 | Novo Nordisk Neutral | Credit Suisse Group | |
| 03.11.22 | Novo Nordisk Overweight | JP Morgan Chase & Co. | |
| 03.11.22 | Novo Nordisk Buy | Deutsche Bank AG | |
| 02.11.22 | A.P. Moeller - Maersk A-S (B) Buy | UBS AG | |
| 02.11.22 | Novo Nordisk Sell | UBS AG | |
| 02.11.22 | Novo Nordisk Conviction Buy List | Goldman Sachs Group Inc. | |
| 02.11.22 | Novo Nordisk Overweight | JP Morgan Chase & Co. | |
| 24.10.22 | Novo Nordisk Conviction Buy List | Goldman Sachs Group Inc. | |
| 14.10.22 | Novo Nordisk Buy | Deutsche Bank AG | |
| 14.10.22 | Novo Nordisk Overweight | Barclays Capital | |
| 07.10.22 | Novo Nordisk Buy | Deutsche Bank AG | |
| 04.10.22 | Novo Nordisk Conviction Buy List | Goldman Sachs Group Inc. | |
| 03.10.22 | Novo Nordisk Overweight | JP Morgan Chase & Co. | |
| 03.10.22 | Novo Nordisk Overweight | Barclays Capital | |
| 21.09.22 | Novo Nordisk Buy | Deutsche Bank AG | |
| 05.09.22 | A.P. Moeller - Maersk A-S (B) Underweight | Barclays Capital | |
| 23.08.22 | Novo Nordisk Sell | UBS AG | |
| 22.08.22 | Novo Nordisk Overweight | JP Morgan Chase & Co. | |
| 17.08.22 | Novo Nordisk Sell | UBS AG | |
| 15.08.22 | Novo Nordisk Overweight | Barclays Capital | |
| 05.08.22 | Novo Nordisk Overweight | JP Morgan Chase & Co. | |
| 05.08.22 | Novo Nordisk Buy | Deutsche Bank AG | |
| 05.08.22 | Novo Nordisk Underperform | Jefferies & Company Inc. | |
| 04.08.22 | Novo Nordisk Neutral | Credit Suisse Group | |
| 04.08.22 | Novo Nordisk Overweight | Barclays Capital | |
| 04.08.22 | A.P. Moeller - Maersk A-S (B) Overweight | JP Morgan Chase & Co. | |
| 04.08.22 | Novo Nordisk Conviction Buy List | Goldman Sachs Group Inc. | |
| 03.08.22 | Novo Nordisk Underperform | Jefferies & Company Inc. | |
| 03.08.22 | Novo Nordisk Overweight | JP Morgan Chase & Co. | |
| 18.07.22 | Novo Nordisk Overweight | Barclays Capital | |
| 14.07.22 | Novo Nordisk Outperform | Bernstein Research | |
| 13.07.22 | Novo Nordisk Conviction Buy List | Goldman Sachs Group Inc. | |
| 12.07.22 | Novo Nordisk Neutral | Credit Suisse Group | |
| 01.07.22 | A.P. Moeller - Maersk A-S (B) Overweight | JP Morgan Chase & Co. | |
| 28.06.22 | Novo Nordisk Sell | UBS AG | |
| 24.06.22 | Novo Nordisk Neutral | UBS AG | |
| 24.06.22 | Novo Nordisk Conviction Buy List | Goldman Sachs Group Inc. | |
| 21.06.22 | Novo Nordisk Buy | Deutsche Bank AG | |
| 16.06.22 | Novo Nordisk Conviction Buy List | Goldman Sachs Group Inc. | |
| 13.06.22 | Novo Nordisk Overweight | Barclays Capital |